biostudies-literatureUnknown10(2)Martino EAMinistero della Salute<h4>Background</h4>Daratumumab-refractory multiple myeloma (Dara-R MM) presents a significant treatment challenge. This study aimed to evaluate the efficacy and survival outcomes of elotuzumab, pomalidomide, and dexamethasone (EloPd) in a large, real-world cohort of patients with Dara-R MM, with particular focus on progression-free survival (PFS) and overall survival (OS).<h4>Materials and methods</h4>This retrospective analysis included 247 Dara-R MM patients treated with EloPd. All patients were also refractory to lenalidomide, with 51.4% to a proteasome inhibitor, thus classified as triple-class refractory (TCR). Survival risk-scoring systems for PFS (progression-free risk score-PRS_DaraR) and OS (survival risk score-SRS_DaraR) were developed to stratify patients basESMO open104084https://www.ebi.ac.uk/biostudies/studies/S-EPMC11761902biostudies-literatureOutcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients.PMC11761902Brunori MMina RZamagni EDe Magistris CCasaluci GMMartino EAQuaresima MBruzzese ATarantini GUccello GAmendola AGalli MRossini BSgherza NDi Raimondo FGentile MPetrucci MTMorabito FRia RTripepi GRago APalumbo GPettine LFranceschini LNeri AFontana RCalifano CDi Renzo NVincelli IDMele GPalmieri SAccardi FBertuglia GMusso MGozzetti AMangiacavalli SNappi DCotzia EAmico VMancuso KBongarzoni VOffidani MDella Pepa RConticello CMusto PCurci PVigna EBarbieri EReddiconto GCerchione CDerudas DZambello RRizzi RMaroccia ABarila GfalseOutcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients.<h4>Background</h4>Daratumumab-refractory multiple myeloma (Dara-R MM) presents a significant treatment challenge. This study aimed to evaluate the efficacy and survival outcomes of elotuzumab, pomalidomide, and dexamethasone (EloPd) in a large, real-world cohort of patients with Dara-R MM, with particular focus on progression-free survival (PFS) and overall survival (OS).<h4>Materials and methods</h4>This retrospective analysis included 247 Dara-R MM patients treated with EloPd. All patients were also refractory to lenalidomide, with 51.4% to a proteasome inhibitor, thus classified as triple-class refractory (TCR). Survival risk-scoring systems for PFS (progression-free risk score-PRS_DaraR) and OS (survival risk score-SRS_DaraR) were developed to stratify patients bas2025-01-01T00:00:00Z2025 Jan2025-04-21T23:54:19.647Z2025-04-05T19:20:37.994ZS-EPMC117619023977832910.1016/j.esmoop.2024.104084